Market Cap | 82.22M | P/E | - | EPS this Y | -6.80% | Ern Qtrly Grth | - |
Income | -48.03M | Forward P/E | -1.35 | EPS next Y | -112.70% | 50D Avg Chg | -10.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -11.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -44.00% |
Recommedations | 2.00 | Quick Ratio | 1.75 | Shares Outstanding | 62.28M | 52W Low Chg | 35.00% |
Insider Own | 30.95% | ROA | -103.87% | Shares Float | 43.11M | Beta | 0.62 |
Inst Own | 15.34% | ROE | - | Shares Shorted/Prior | 5.26M/5.01M | Price | 1.38 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 60,974 | Target Price | - |
Oper. Margin | - | Earnings Date | Nov 11 | Volume | 53,138 | Change | -1.43% |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
HC Wainwright & Co. | Buy | Aug 16, 24 |
HC Wainwright & Co. | Buy | Apr 9, 24 |
HC Wainwright & Co. | Buy | Apr 1, 24 |
HC Wainwright & Co. | Buy | Aug 15, 23 |
HC Wainwright & Co. | Buy | May 17, 23 |
HC Wainwright & Co. | Buy | Mar 3, 23 |
HC Wainwright & Co. | Buy | May 17, 22 |
HC Wainwright & Co. | Buy | Apr 16, 21 |
HC Wainwright & Co. | Buy | Aug 13, 20 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
ELDRED KARY | Director Director | Jan 16 | Buy | 1.7858 | 500 | 893 | 49,313 | 01/16/24 |
Uihlein Richard E | Director Director | Sep 26 | Option | 3.85 | 2,236,204 | 8,609,385 | 10,235,495 | 09/27/23 |
ELDRED KARY | Director Director | Jul 19 | Buy | 1.786 | 1,598 | 2,854 | 48,813 | 07/20/23 |
ELDRED KARY | Director Director | Feb 21 | Buy | 1.5911 | 1,000 | 1,591 | 47,215 | 02/21/23 |
LEWIS JOEL | President and CEO President and CEO | Feb 16 | Buy | 1.52 | 1,000 | 1,520 | 1,000 | 02/21/23 |
ELDRED KARY | Director Director | Jan 25 | Buy | 1.11 | 1,300 | 1,443 | 46,215 | 01/26/23 |
FREEMAN KEVIN D | Director Director | Oct 28 | Buy | 1.41 | 10,000 | 14,100 | 75,000 | 10/31/22 |
10X Fund, L.P. | 10% Owner 10% Owner | Jul 27 | Sell | 2.087 | 10,000 | 20,870 | 6,168,940 | 08/15/22 |
10X Fund, L.P. | 10% Owner 10% Owner | Jul 22 | Sell | 2.087 | 10,000 | 20,870 | 6,168,940 | 08/09/22 |
Zordani Richard A. Jr. | Director Director | Jul 28 | Buy | 2.5 | 5,000 | 12,500 | 29,583 | 07/29/22 |
FREEMAN KEVIN D | Director Director | May 19 | Buy | 1.3299 | 5,000 | 6,650 | 65,000 | 05/20/22 |
10X Fund, L.P. | 10% Owner 10% Owner | Feb 02 | Sell | 2.10 | 10,000 | 21,000 | 6,178,940 | 02/04/22 |
Schwartz Elissa J. | Director Director | Jan 21 | Buy | 2 | 1,000 | 2,000 | 1,000 | 01/24/22 |
FREEMAN KEVIN D | Director Director | Jan 19 | Buy | 1.9612 | 5,000 | 9,806 | 50,000 | 01/19/22 |
Zordani Richard A. Jr. | Director Director | Jan 14 | Buy | 2.02 | 5,000 | 10,100 | 19,583 | 01/18/22 |
10X Fund, L.P. | 10% Owner 10% Owner | Jan 11 | Sell | 2.10 | 10,000 | 21,000 | 6,188,940 | 01/13/22 |